Table 1 Clinical features and genetic variants confirmed in index cases and available affected relatives.

From: Aryl hydrocarbon receptor interacting protein and syndromic gene variants detected in Turkish isolated pituitary adenoma families by whole exome sequencing

Index number /FIPA type

Sex (F/M)/ Age (yrs)

Adenoma type/ size (mm)

Gene

Chr Position

GRCh37 - hg19

Variant

Consequence

Pathogenicity

In Silico Tools

GERP++

DANN

SIFT

LIST-S2

ALPHA MISSENSE

1/ HO

F/23

PRL-secreting/9

NR5A1

(SF1)

Chr9:127262707 C > T

NM_004959.5:c.532 G > A

p.(Gly178Arg)

ACMG: VUS ClinVar: Not reported

4.84

D (0.9989)

T (0.56)

T (0.8883)

A (0.378)

   

PKD1

Chr16:2150248 C > T

NM_001009944.3:c.9631 G > A

p.(Ala3211Thr)

ACMG: VUS ClinVar: VUS

4.69

T (0.7633)

T (0.56)

T (0.3465)

LB (0.057)

2/HO

M/22

GH-secreting/15

TINF2

Chr14:24710039 T > TC

NM_001099274.3: c.646dup

p.(Glu216GlyfsTer61)

ACMG: Pathogenic ClinVar: Not reported

NA

NA

NA

NA

NA

   

ATP2B3

ChrX:152830460 G > C

NM_001001344.3:c.3241 G > C

p.(Glu1081Gln)

ACMG: VUS ClinVar: Not reported

4.63

D (0.9977)

T (0.07)

D (0.9383)

LB (0.114)

3/HO

M/33

GH-secreting/14

RUNX2

Chr6:45630999 C > T

NM_001024630.4:c.1169 C > T

p.(Pro390Leu)

ACMG: VUS ClinVar: Not reported

5.31

D (0.9950)

T (0.14)

T (0.4790)

LP (0.626)

4/HO

M/59

PRL-secreting/22

LGALS3

Chr14:55604881 C > G

NM_002306.3 :c.137 C > G

p.(Pro46Arg)

ACMG: VUS ClinVar: Not reported

5.34

T (0.9829)

D (0)

D (0.8980)

A (0.5)

   

DRD4

Chr11:640307 G > A

NM_000797.4: c.1057 + 1 G > A

splice donor

ACMG: VUS ClinVar: Not reported

NA

NA

NA

NA

NA

5/HO

F/27

PRL-secreting/6

SYTL3

Chr6:159129392 G > T

NM_001242395.1:c.485 G > T

p.(Ser162Ile)

ACMG: LB ClinVar: Not reported

4.59

T (0.9879)

D (0.16)

NA

LB (0.152)

6/HO

F/43

GH-secreting/14

SQSTM1

Chr5:179260612 CAGG > C

NM_003900.4:c.1001_1003del

p.(Gly334del)

ACMG: VUS ClinVar: VUS

NA

NA

NA

NA

NA

   

AIP

Chr11:67258381 C > T

NM_003977.2:c.910 C > T

p.(Arg304Ter)

ACGM: VUS ClinVar: Pathogenic

5.39

D (0.9964)

NA

NA

NA

7/HO

M/32

GH-secreting/60

ATP2B3

ChrX:152818590 G > A

NM_001001344.2:c.1921 G > A

p.(Asp641Asn)

ACMG: VUS ClinVar: Not reported

5.44

D (0.9986)

T (0.23)

D (0.9018)

LB (0.102)

   

TSC1

Chr9:135781415 C > T

NM_001162427.1: c.1550 G > A

p.(Arg517Gln)

ACGM: VUS ClinVar: LB

6.05

D (0.991)

T (0.23)

NA

LB (0.084)

   

SSTR4

Chr20:23017082 T > C

NM_001052.2:c.962 T > C

p.(Phe321Ser)

ACMG: VUS ClinVar: Not reported

3.65

T (0.7532)

T (1)

T (0.5168)

LB (0.099)

   

FGFR2

Chr10:123260394 T > G

NM_022970.3:c.1510 A > C

p.(Ile504Leu)

ACGM : VUS ClinVar: Not reported

5.76

T (0.9756)

T (0.36)

T ( 0.6349)

LB (0.105)

8/HO

F/38

GH-secreting/18

BRAF

Chr7:140434597 G > GA

NM 004333.4:c.2128-28dup

Intronic

ACGM: VUS ClinVar: VUS

NA

NA

NA

NA

NA

9/HO

M/51

PRL-secreting/15

RUNX2

Chr6:45390433 G > GCAGCAGCAGCAA

NM_001024630.4:c.174_185dup

p.(Gln68_Gln71dup)

ACGM: VUS ClinVar: Conflicting classifications of pathogenicity

NA

NA

NA

NA

NA

10/HO

M/32

GH-secreting/7

APC

Chr5:112173317 A > G

NM_000038.5:c.2026 A > G

p.(Ile676Val)

ACGM : VUS ClinVar: VUS

5.99

D (0.9966)

T (0)

NA

LB (0.232)

11/HE

F/47

GH-secreting/12

RARB

Chr3:25215908 C > T

NM_001290216.3:c.20 C > T

p.(Ala7Val)

ACMG : VUS ClinVar: Not reported

5.88

D (0.9972)

D (0.03)

T (0.5300)

LB (0.075)

   

SYTL3

Chr6:159086521 G > A

NM_001242395.2:c.205 G > A

p.(Val69Met)

ACGM: LB ClinVar: Not reported

5.8

T (0.9575)

T (0.05)

NA

LB (0.102)

12/HE

M/37

GH-secreting/23

AIP

Chr11:67257786 G > C

NM_003977.2:c.646-1 G  > C

Splice acceptor site

(intron 4–5)

ACMG: Pathogenic ClinVar: Not reported

NA

NA

NA

NA

NA

   

LGALS3

Chr14:55611955 T > C

NM_002306.3:c.719 T > C

p.(Ile240Thr)

ACMG : VUS ClinVar: Not reported

5.77

D (0.9971)

D (0)

D (0.8707)

LP (0.658)

   

SUFU

Chr10:104356982 C > T

NM_016169.3:c.842 C > T

p.(Pro281Leu)

ACGM : VUS ClinVar: VUS

6.03

D (0.9952)

D (0.3)

D (0.9881)

LB (0.14)

13/HE

M/27

GH-secreting/40

AIP

Chr11:67254618 C > T

NM_003977.2:c.241 C > T

p.(Arg81Ter)

ACMG: Pathogenic ClinVar: Pathogenic

5.22

D (0.9978)

NA

NA

NA

14/HE

M/30

PRL-secreting/29

SDHB

Chr1:17354257 T > C

NM_003000.2:c.527 A > G

p.(Glu176Gly)

ACGM : VUS ClinVar: VUS

5.76

D (0.9978)

D (0)

D (0.9671)

A (0.388)

15/HE

F/42

ACTH-secreting/12

RARB

Chr3:25216009 C > A

NM_001290216.3:c.121 C > A

p.(Leu41Ile)

ACMG : VUS ClinVar: Not reported

5.88

D (0.9935)

T (0.04)

T (0.3260)

LB (0.071)

16/HE

M/60

PRL-secreting/45

DRD3

Chr3:113890746 A > G

NM_000796.3:c.94 T > C

p.(Tyr32His)

ACGM : VUS ClinVar: Not reported

5

D (0.9982)

D (0)

D (0.8829)

LB (0.203)

17/HE

F/22

PRL-secreting/12

NF1

Chr17:29562948 A > G

NM_000267.3:c.3883 A > G

p.(Thr1295Ala)

ACGM: VUS ClinVar: Conflicting classifications of pathogenicity

5.94

T (0.9850)

T (0.43)

T (0.7980)

LB (0.055)

18/HE

F/19

PRL-secreting/18

NPR2

Chr9:35800044 A > G

NM_003995.3:c.1013 A > G

p.(Tyr338Cys)

ACGM: VUS ClinVar: VUS

5.69

D (0.9984)

D (0)

D (0.9622)

LP (0.656)

19/HE

M/36

ACTH-secreting/6

PTTG1

Chr5:159851328 A > G

NM_004219.2:c.361 A > G

p.(Asn121Asp)

ACGM : VUS ClinVar: Not reported

5.17

T (0.9866)

T (0.73)

NA

LB (0.106)

20/HE

F/46

ACTH-secreting/5

CDH23

Chr10:73570263 C > T

NM_001171934.1:c.2294 C > T

p.(Ala765Val)

ACGM : VUS ClinVar: VUS

5.67

D (0.9973)

(0.02)

D (0.9498)

A (0.516)

   

KCNQ1

Chr11:2683253 G > A

NM_181798.1:c.1456 G > A

p.(Ala486Thr)

ACGM: VUS ClinVar: VUS

4.59

T (0.9082)

T (0.19)

T (0.8037)

LB (0.078)

  1. FIPA, Familial Isolated Pituitary Adenoma; HO, Homogeneous; HE, Heterogeneous; Age: At diagnosis (years); F, Female; M, Male; PRL, prolactin hormone; GH, growth hormone; ACTH, adrenocorticotropic hormone; Chr, chromosomal; ACMG, American College of Medical Genetics classification of variants; VUS, Variant of Uncertain Significance; LB, Likely benign; NA, Not Available. D, Damaging, T, Tolerated; GERP++, measure of evolutionary conservation (score ≥ 2 considered constrained); DANN, Pathogenicity scored 0–1 (higher values indicative of deleteriousness); SIFT, deleteriousness based on amino acid substitutions; LIST-S2, predicts the deleteriousness of amino acid mutations in proteomes; A, Ambiguous. All genetic variants detected were heterozygous except for variations in BRAF and PKD1 genes.